Cibenzoline

Cibenzoline is a class Ia antiarrhythmic active molecule with low anticholinergic activity. Cibenzoline is a KATP channel inhibitor, acting through the pore forming subunit Kir6.2, with an IC50 of 22.2 μM. Cibenzoline inhibits IKr and IKs currents with IC50 values of 8.8 μM and 12.3 μM, respectively. Cibenzoline is used in the study of cardiac diseases. In addition, Cibenzoline can induce hypoglycemia[1][2][3][4].

Product Specifications

CAS Number

[53267-01-9]

Product Name Alternative

Cifenline; Ro 22-7796

UNSPSC

12352005

Hazard Statement

H302, H315

Target

Potassium Channel

Type

Reference compound

Related Pathways

Membrane Transporter/Ion Channel

Applications

Neuroscience-Neuromodulation

Field of Research

Metabolic Disease; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/cibenzoline.html

Concentration

10mM

Purity

95.08

Solubility

DMSO : 100 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

C1(C2CC2(C3=CC=CC=C3)C4=CC=CC=C4)=NCCN1

Molecular Formula

C18H18N2

Molecular Weight

262.36

Precautions

H302, H315

References & Citations

[1]Mukai E, et al. The antiarrhythmic agent cibenzoline inhibits KATP channels by binding to Kir6.2. Biochem Biophys Res Commun. 1998;251 (2) :477-481.|[2]Hamada M, et al. Class Ia antiarrhythmic drug cibenzoline: a new approach to the medical treatment of hypertrophic obstructive cardiomyopathy. Circulation. 1997;96 (5) :1520-1524.|[3]Satoh H. Comparative actions of cibenzoline and disopyramide on I (Kr) and I (Ks) currents in rat sino-atrial nodal cells. Eur J Pharmacol. 2000 Oct 27;407 (1-2) :123-9.|[4]Takahashi Y, et al. Pharmacodynamics of cibenzoline-induced hypoglycemia in rats. Drug Metab Pharmacokinet. 2011 Jun;26 (3) :242-7.